These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 11429125)

  • 61. Detailed analysis of CD4+ Th responses to envelope and Gag proteins of simian immunodeficiency virus reveals an exclusion of broadly reactive Th epitopes from the glycosylated regions of envelope.
    Sarkar S; Kalia V; Murphey-Corb M; Montelaro RC
    J Immunol; 2002 Apr; 168(8):4001-11. PubMed ID: 11937557
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus.
    Murphy CG; Lucas WT; Means RE; Czajak S; Hale CL; Lifson JD; Kaur A; Johnson RP; Knipe DM; Desrosiers RC
    J Virol; 2000 Sep; 74(17):7745-54. PubMed ID: 10933680
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Enhanced safety and efficacy of live attenuated SIV vaccines by prevaccination with recombinant vaccines.
    Jones L; Ahmad S; Chan K; Verardi P; Morton WR; Grant R; Yilma T
    J Med Primatol; 2000 Aug; 29(3-4):231-9. PubMed ID: 11085585
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Live attenuated rubella vectors expressing SIV and HIV vaccine antigens replicate and elicit durable immune responses in rhesus macaques.
    Virnik K; Hockenbury M; Ni Y; Beren J; Pavlakis GN; Felber BK; Berkower I
    Retrovirology; 2013 Sep; 10():99. PubMed ID: 24041113
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Role of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVmne in protection against homologous cloned and uncloned virus challenge in Macaques.
    Polacino PS; Stallard V; Klaniecki JE; Pennathur S; Montefiori DC; Langlois AJ; Richardson BA; Morton WR; Benveniste RE; Hu SL
    J Virol; 1999 Oct; 73(10):8201-15. PubMed ID: 10482571
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Protection of macaques with a simian immunodeficiency virus envelope peptide vaccine based on conserved human immunodeficiency virus type 1 sequences.
    Shafferman A; Jahrling PB; Benveniste RE; Lewis MG; Phipps TJ; Eden-McCutchan F; Sadoff J; Eddy GA; Burke DS
    Proc Natl Acad Sci U S A; 1991 Aug; 88(16):7126-30. PubMed ID: 1871125
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251.
    Gómez-Román VR; Patterson LJ; Venzon D; Liewehr D; Aldrich K; Florese R; Robert-Guroff M
    J Immunol; 2005 Feb; 174(4):2185-9. PubMed ID: 15699150
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160.
    Hu SL; Abrams K; Barber GN; Moran P; Zarling JM; Langlois AJ; Kuller L; Morton WR; Benveniste RE
    Science; 1992 Jan; 255(5043):456-9. PubMed ID: 1531159
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Vaccine protection from CD4+ T-cell loss caused by simian immunodeficiency virus (SIV) mac251 is afforded by sequential immunization with three unrelated vaccine vectors encoding multiple SIV antigens.
    Koopman G; Mortier D; Hofman S; Niphuis H; Fagrouch Z; Norley S; Sutter G; Liljeström P; Heeney JL
    J Gen Virol; 2004 Oct; 85(Pt 10):2915-2924. PubMed ID: 15448353
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Highly attenuated SIVmac142 is immunogenic but does not protect against SIVmac251 challenge.
    Denesvre C; Le Grand R; Boissin-Cans F; Chakrabarti L; Hurtrel B; Vaslin B; Dormont D; Sonigo P
    AIDS Res Hum Retroviruses; 1995 Nov; 11(11):1397-406. PubMed ID: 8573398
    [TBL] [Abstract][Full Text] [Related]  

  • 71. DNA/long peptide vaccination against conserved regions of SIV induces partial protection against SIVmac251 challenge.
    Koopman G; Beenhakker N; Nieuwenhuis I; Doxiadis G; Mooij P; Drijfhout JW; Koestler J; Hanke T; Fagrouch Z; Verschoor EJ; Bontrop RE; Wagner R; Bogers WM; Melief CJ
    AIDS; 2013 Nov; 27(18):2841-51. PubMed ID: 24105029
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Longitudinal study to assess the safety and efficacy of a live-attenuated SHIV vaccine in long term immunized rhesus macaques.
    Yankee TM; Sheffer D; Liu Z; Dhillon S; Jia F; Chebloune Y; Stephens EB; Narayan O
    Virology; 2009 Jan; 383(1):103-11. PubMed ID: 18986665
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Passively transferred antibodies directed against conserved regions of SIV envelope protect macaques from SIV infection.
    Lewis MG; Elkins WR; McCutchan FE; Benveniste RE; Lai CY; Montefiori DC; Burke DS; Eddy GA; Shafferman A
    Vaccine; 1993 Oct; 11(13):1347-55. PubMed ID: 7507625
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Priming T-cell responses with recombinant measles vaccine vector in a heterologous prime-boost setting in non-human primates.
    Bolton DL; Santra S; Swett-Tapia C; Custers J; Song K; Balachandran H; Mach L; Naim H; Kozlowski PA; Lifton M; Goudsmit J; Letvin N; Roederer M; Radošević K
    Vaccine; 2012 Sep; 30(41):5991-8. PubMed ID: 22732429
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Immunization with live attenuated simian immunodeficiency virus induces strong type 1 T helper responses and beta-chemokine production.
    Gauduin MC; Glickman RL; Ahmad S; Yilma T; Johnson RP
    Proc Natl Acad Sci U S A; 1999 Nov; 96(24):14031-6. PubMed ID: 10570193
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Characterization of CD4+ T helper cell fine specificity to the envelope glycoproteins of simian immunodeficiency virus.
    Sarkar S; Kalia V; Murphey-Corb M; Montelaro RC
    J Med Primatol; 2002 Aug; 31(4-5):194-204. PubMed ID: 12390542
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Mechanisms of protection induced by attenuated simian immunodeficiency virus. II. Lymphocyte depletion does not abrogate protection.
    Stebbings R; Stott J; Almond N; Hull R; Lines J; Silvera P; Sangster R; Corcoran T; Rose J; Cobbold S; Gotch F; McMichael A; Walker B
    AIDS Res Hum Retroviruses; 1998 Sep; 14(13):1187-98. PubMed ID: 9737590
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Circumventing antivector immunity by using adenovirus-infected blood cells for repeated application of adenovirus-vectored vaccines: proof of concept in rhesus macaques.
    Sun C; Feng L; Zhang Y; Xiao L; Pan W; Li C; Zhang L; Chen L
    J Virol; 2012 Oct; 86(20):11031-42. PubMed ID: 22855499
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Antibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIV(mac251) acquisition in an immunization regimen that mimics the RV-144 Thai trial.
    Pegu P; Vaccari M; Gordon S; Keele BF; Doster M; Guan Y; Ferrari G; Pal R; Ferrari MG; Whitney S; Hudacik L; Billings E; Rao M; Montefiori D; Tomaras G; Alam SM; Fenizia C; Lifson JD; Stablein D; Tartaglia J; Michael N; Kim J; Venzon D; Franchini G
    J Virol; 2013 Feb; 87(3):1708-19. PubMed ID: 23175374
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The effect of immunization on chemokines and CCR5 and CXCR4 coreceptor functions in SIV binding and chemotaxis.
    Wang Y; Tao L; Mitchell E; Bergmeier L; Doyle C; Lehner T
    Vaccine; 1999 Apr; 17(15-16):1826-36. PubMed ID: 10217580
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.